Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561995 | 0.84 | MMP1 (0.49) | CTSKCTSLCTSSPREPMMP1 | |
| SCHEMBL7563529 | 0.80 | CTSL (0.52) | CTSKCTSLCTSSMMP1ADAM17 | |
| SCHEMBL7560380 | 0.79 | CTSK (0.49) | CTSKCTSLCTSSPREPMMP1 | |
| SCHEMBL7673959 | 0.78 | MMP1 (0.45) | CTSKCTSLCTSSPREPHCRTR1 | |
| SCHEMBL7561086 | 0.76 | CTSK (0.44) | CTSKCTSLCTSSSMN1; SMN2MMP1 | |
| SCHEMBL7164688 | 0.76 | CTSK (0.55) | CTSKCTSLCTSS | |
| SCHEMBL7533265 | 0.76 | MMP1 (0.46) | CTSKCTSLCTSSPREPMMP1 | |
| SCHEMBL7458804 | 0.75 | CTSK (0.44) | CTSKCTSLCTSSMMP1ADAM17 | |
| SCHEMBL7524135 | 0.75 | MMP1 (0.47) | CTSKCTSLCTSSGAASMN1; SMN2 | |
| SCHEMBL7532726 | 0.74 | CTSK (0.55) | CTSKCTSLCTSSPREPMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSK 22/4885CTSL 4/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.